Amyloid-beta

Amyloid-beta (Aβ) is a peptide, typically composed of 36 to 43 amino acids, that plays a central role in the pathology of Alzheimer's disease. It is not an abnormal protein in itself but is derived from a larger, naturally occurring membrane protein called the amyloid precursor protein (APP), which is found in many tissues but is particularly concentrated in the synapses of neurons. Aβ is formed when APP is sequentially cleaved by two enzymes, beta-secretase and gamma-secretase. While this process occurs normally, in Alzheimer's disease, an imbalance between the production and clearance of Aβ leads to its accumulation.

The individual Aβ peptides (monomers) can misfold and aggregate, sticking to one another to form a range of structures. These begin as small, soluble clusters called oligomers, which are now considered by many scientists to be the most toxic form of Aβ, capable of disrupting synaptic function and communication between neurons. Over time, these oligomers can further assemble into larger, insoluble threads called fibrils, which ultimately deposit in the brain as dense, extracellular formations known as amyloid plaques. While the plaques themselves are a defining feature of Alzheimer's, their direct correlation with cognitive decline is complex, and the soluble oligomers are thought to be more directly damaging to brain cells.

The discovery and study of amyloid-beta are foundational to the amyloid cascade hypothesis, the dominant theory of Alzheimer's disease pathogenesis for several decades. First proposed in the early 1990s, this hypothesis posits that the abnormal accumulation of Aβ in the brain is the primary initiating event that triggers a complex downstream cascade. This cascade includes inflammation, oxidative stress, the formation of neurofibrillary tangles (composed of another protein, tau), synaptic dysfunction, and widespread neuronal death, which collectively manifest as progressive cognitive impairment and dementia. While the hypothesis has been instrumental in guiding research, it has also evolved. The focus has shifted from the insoluble plaques to the more toxic soluble oligomers, and it is now widely accepted that other factors, including tau pathology, genetics (like the APOE gene), and neuroinflammation, interact with Aβ to drive the disease.

For patients and the medical community, amyloid-beta is significant for two primary reasons: as a diagnostic biomarker and as a therapeutic target. The presence of elevated Aβ can be detected years, or even decades, before the onset of clinical symptoms. This is done through cerebrospinal fluid (CSF) analysis or through advanced imaging techniques like positron emission tomography (PET) scans that can visualize amyloid plaques directly. These tools are crucial for early diagnosis and for enrolling individuals in clinical trials.

Furthermore, Aβ has been the principal target for disease-modifying therapies for Alzheimer's. A class of drugs known as monoclonal antibodies (e.g., lecanemab, donanemab) has been developed to bind to and promote the clearance of Aβ from the brain. These treatments have shown a modest ability to slow cognitive decline in early-stage Alzheimer's, representing a major milestone in treatment. The ongoing development and refinement of anti-amyloid therapies remain a critical frontier in the quest to effectively treat and ultimately prevent Alzheimer's disease.